Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses results of a study that determined lenalidomide (Revlimid) is a highly-effective maintenance therapy in myeloma patients of all ages.
In a study of about 850 patients, lenalidomide was found to increase progression-free survival (PFS). Across the entire cohort of patients, PFS increased by approximately 22 months. In the transplant eligible patients, PFS was increased by approximately 28 months. Even for the older population, the PFS increased by more than 12 months, Jackson says.
The results show that lenalidomide maintenance is now standard of care for frontline treatment in patients with myeloma, Jackson says.